Brawn Biotech swings to ₹94 lakh profit, but the filing adds nothing new
The nano-cap drug firm's first full-year profit is a known trend from prior quarters. This is a routine compliance filing.
— 1 earlier story on Brawn Biotech Ltd. →What's new
- Brawn Biotech reported a full-year net profit of ₹94.06 lakhs for FY2026.
- This reverses a net loss of ₹179.81 lakhs in the prior financial year.
- The audited annual result is a scheduled SEBI filing, not a surprise.
Why this matters
The swing to profitability is real, but it's the story of the year, not the day. Quarterly filings would have already shown the path to black, so the market has had time to digest the trend. The annual number confirms it.
What we're watching
- The sustainability of the profit on a ₹6.00 crore market cap.
- Whether the next quarterly result builds on the FY2026 outcome.
- Any new operational detail beyond this compliance release.
The full read
Brawn Biotech is in the black. ₹94.06 lakhs profit in FY2026, after a ₹179.81 lakh loss the year before. That's the story. The market cap is just ₹6.00 crores, so every lakh matters. But this is a compliance filing. The quarterly results would have already telegraphed the turnaround, so investors have had time to price it in. Hardly a catalyst. The full-year profit is a milestone for the company, but not for the market.
Questions answered
- How much did Brawn Biotech earn in FY2026?
- The company posted a net profit of ₹94.06 lakhs, a swing from a net loss of ₹179.81 lakhs in the prior year.
- Why is this filing considered routine?
- Audited annual results are mandatory SEBI filings. The market tracks quarterly progress, so the full-year number confirms a trend that was already visible.
- What is the company's market capitalisation?
- Brawn Biotech has a market capitalisation of ₹6.00 crores.
Story so far
All notes on BRAWN →- 29 May 2026 · 6:22 PM IST Brawn Biotech swings to ₹94 lakh profit, but the filing adds nothing new
- 1d ago Brawn Biotech posts FY26 profit, but Q4 was weak